StockData
NewcelX Ltd. logo

NewcelX Ltd. (NCEL) shareholders

NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 4/30
$2.54−0.15 (-5.58%)

Close on Nov 20, 2026Market cap $12.19MP/E 1.2Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.2%
0M of 5M shares
Institutional holders
4
2 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $375.00K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
League Jinn Sarl
Joint filing with Julien Ruggieri (25.30%)
1,316,26725.30%13D (active)Apr 27, 2026
Julien Ruggieri
Joint filing with League Jinn Sarl (21.60%)
988,99621.60%13G (passive)Oct 30, 2025
Michel Revel940,78720.20%13D (active)Oct 30, 2025
Ronald Hafner557,13113.20%13D (active)May 22, 2025
Clover Wolf Capital - Limited Partnership
Joint filing with Adi Wolf (7.50%)
343,1207.50%13G (passive)Oct 30, 2025
Ronen Twito272,3996.00%13D (active)Oct 30, 2025
Alpha Capital Anstalt246,9969.99%13G (passive)Oct 10, 2024
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
129,4759.99%13G (passive)Sep 30, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NCELValueChange% of portfolio
Hrt Financial LP11,1990.23%$40.00KNew0.00%
Jones Financial Companies Lllp7000.01%$2.55KNew0.00%
Caitong International Asset Management Co., Ltd90.00%$33+80.00%
CoreCap Advisors, LLC30.00%$11–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202640M0.2%2 / 10 / 20M0M
Q1 202640M0.0%3 / 00 / 00M0M
Q4 202510M0.0%0 / 01 / 00M0M
Q3 202510M0.0%0 / 00 / 00M0M
Q2 202510M0.0%1 / 00 / 00M0M
Q3 202400M0.0%0 / 00 / 100M0M
Q2 2024100M0.4%3 / 21 / 10M0M
Q1 202480M0.4%4 / 10 / 10M0M
Q4 202350M0.3%0 / 01 / 20M0M
Q3 202370M0.3%1 / 12 / 30M0M
Q2 202390M0.3%3 / 21 / 10M0M
Q1 202370M0.3%4 / 10 / 20M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Michel RevelCSO and Director, 10% owner957,53019.96%Apr 29, 2026
Ronen TwitoChairman and CEO, Director272,3995.68%Mar 18, 2026
Kfir MolakandovVP of R&D––Mar 18, 2026
Omri HagaiChief Financial Officer––Mar 18, 2026
Olivier SamuelDirector81,8181.71%Apr 29, 2026
Tamar GaliliDirector––Mar 18, 2026
Alexander ZwyerDirector––Mar 18, 2026
Eran Israel IohanDirector––Mar 18, 2026
Liora OrenDirector––Mar 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Olivier Samuel
Director
Apr 27, 2026Buy+81,818$2.75$225.00K81,818
Michel Revel
CSO and Director, 10% owner
Apr 27, 2026Buy+54,545$2.75$150.00K957,530

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.65%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+6.9%
From 0M shares
Short volume, 20 days
31.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NewcelX's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?